Av-Phos 250 Neutral
100/100
This product looks safe
- No ingredients exceed tolerable upper intake levels
- 67% of ingredients have research evidence
A
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Label Data
1 Tablet(s)
Serving Size
100
Servings
Other Combinations
Product Type
67%
Evidence Coverage
Supplement Facts — Evidence Check
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
📊 Market median: 4002.0mg (1 products)
📚 20 studies (Tier A: 0, B: 2)
250 mg
(25% DV)
✅ Within RDA (0.4× RDA of 700 mg)
📚 12 studies (Tier A: 0, B: 3)
Sodium
298 mg
Potassium
45 mg
Label Claims — Verification
❓
Nutrient
All Other (98% of products)
Structure/Function (89% of products)
Nutrient (76% of products)
Target Groups
Adult (18 - 50 Years)
Product Information
📋 Directions for Use
Must be used under the supervision of a physician.
🧪 Formulation Notes
Prescription phosphorous Supplying 250 mg per tablet
Additional Information
NDC 42291-152-01 Peel here
Product Details
Research Evidence
46
Research Sources
55
Avg Quality Score
23
Meta Analysis
7
Systematic Review
7
Rct
4
Clinical Trial
2
Other
1
Guideline
1
Regulatory Source
A
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
A
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)
B
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
B
Radiographic and clinical outcomes of silicate-substituted calcium phosphate (SiCaP) bone grafts in spinal fusion: Systematic review and meta-analysis
B
ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium.
B
Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
B
The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Compare Similar Products
Virt-Phos 250 Neutral
Virtus Pharmaceuticals
100
Essential Minerals For Women & Men
Nature's Measure
100
Calcium & Phosphorus With Vitamin D
Sunmark
100
Replace SR
Endurance Products Company
100
Replace SR
Endurance Products Company
100